Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Accounts Payables: 2019-2025

Historic Accounts Payables for C4 Therapeutics (CCCC) over the last 5 years, with Sep 2025 value amounting to $1.3 million.

  • C4 Therapeutics' Accounts Payables fell 11.37% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 11.37%. This contributed to the annual value of $1.3 million for FY2024, which is 8.16% down from last year.
  • Latest data reveals that C4 Therapeutics reported Accounts Payables of $1.3 million as of Q3 2025, which was down 39.85% from $2.2 million recorded in Q2 2025.
  • C4 Therapeutics' 5-year Accounts Payables high stood at $4.5 million for Q4 2021, and its period low was $683,000 during Q1 2025.
  • For the 3-year period, C4 Therapeutics' Accounts Payables averaged around $1.4 million, with its median value being $1.3 million (2025).
  • Per our database at Business Quant, C4 Therapeutics' Accounts Payables crashed by 73.99% in 2022 and then soared by 142.72% in 2025.
  • C4 Therapeutics' Accounts Payables (Quarterly) stood at $4.5 million in 2021, then crashed by 73.99% to $1.2 million in 2022, then increased by 23.38% to $1.4 million in 2023, then decreased by 8.16% to $1.3 million in 2024, then fell by 11.37% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $2.2 million for Q2 2025, and $683,000 during Q1 2025.